冠心病降脂治疗新进展——Inclisiran

New development of lipid-lowering therapy of coronary heart disease:Inclisiran

长期口服他汀类药物依从性差,而Inclisiran给药间期长达3个月至半年,患者的依从性明显提高。本文概述了Inclisiran的最新进展,汇总了Inclisiran的II期和III期临床试验研究结果,Inclisiran的副作用和其正在进行的相关临床试验,并介绍了Inclisiran的临床应用现状。

Because of high rate of nonadherence to statins,the subcutaneously injection of Inclisiran therapy intervals are from 3 months to 6 months,which will increase the patients'adherence to the Inclisiran therapy.In this review,we summarize the latest advances of Inclisiran,and review the phase 2 and phase 3 clinical trials results,adverse events,and the clinical trials results in progress of Inclisiran.Finally,we discuss the current status of Inclisiran in the clinical works.